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Menstrual-derived stem cells (MenSCs) are a new source of mesenchymal stem cells
isolated from the menstrual fluid. Currently, there is a growing interest in their clinical
potential due to fact that they are multipotent, highly proliferative, and easy to obtain in
a non-invasive manner. Sampling can be repeated periodically in a simplified and repro-
ducible manner devoid of complications that no existing cell source can match. MenSCs
are also free of ethical dilemmas, and display novel properties with regard to presently
known adult derived stem cells. This review details their distinctive biological properties
regarding immunophenotype and function, proliferation rate, differentiation potential, and
paracrine effects mediated by secreted factors.Their possible role in antenatal diagnosis is
also discussed. While more insight on their immunomodulatory and diagnostic properties
is needed, the impact of clinical and epidemiological factors, such as age, use of contra-
ceptives, or hormonal status still requires further investigations to properly assess their
current and future use in clinical application and diagnosis.
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INTRODUCTION
Mesenchymal stem cells (MSCs) are pluripotent progenitor cells
with self-renewing capacity and potential ability of differentiat-
ing into various specialized cell types under specific conditions.
Adult stem cells are derived from different sources, such as bone
marrow, adipose tissue (AD), or post-natal tissues such as umbili-
cal cords and placenta. MSC have recently received a great deal
of attention because of their therapeutic potential for treating
immune mediated or neoplasic human diseases. However, the
difficulty of isolating adult stem cells from diverse tissues due
to the invasiveness of the extraction methods and the need for
in vitro expansion are limiting points in their clinical applica-
tions. Therefore, many studies have focused on the search for
novel stem cells that can be effectively used for therapeutic pur-
poses without these limitations. While each clinical application
will have its own selection criteria for choosing the most appro-
priate MSCs source, a representation of a decision tree based on
six sources of MSCs and five different criteria related to their avail-
ability, isolation procedure, and different properties is presented
in Figure 1.
A study published in 2007 identified and characterized a new
source of stem cells within the menstrual fluid. They showed that
menstrual-derived stem cells (MenSCs) are a highly proliferative
stem cell population that is able to differentiate under standard
laboratory conditions into specific-tissue cells of three germ layers
(1). These cells present a good alternative to MSCs present in other
sources such as bone marrow, adipose, and post-birth tissues due
to the fact that they have higher proliferation rates and are of easy
access with no need for surgical procedures or hospitalization, a
feature that none of the existing sources can match. They are also
free of ethical dilemmas and display novel properties with regard
to the presently known adult derived stem cells.
ARE MenSCs JUST ANOTHER MSCs SOURCE?
A detailed characterization of the MenSCs is a pre-requisite
for a head-to-head comparison with related cells from other
sources. This will pave the way for evaluating possible advan-
tages of MenSCs and also their safety/efficacy profile for clinical
applications.
PROLIFERATION, SENESCENCE, AND MIGRATION
Meng et al. showed that MenSCs from the menstrual fluid of young
healthy women grew at a rate of one doubling every 19.4 h, which
is twice faster than bone marrow-derived MSCs (BM-MSCs), esti-
mated at 40–45 h in early passages (1). In an effort to understand
such a high proliferation rate, one should look back at their ori-
gin and physiological function. The endometrium consists of the
epithelial layer and the underlying lamina propria. This layer is
structurally and functionally divided into the functionalis – with
glands extending from the surface epithelium – and the lower
basalis (2). The upper two-thirds of the functionalis are shed
during menstruation and are a major part of the collected men-
strual fluid. Recent studies have provided ample evidence for
the existence of stem/progenitor cells in human endometrium.
Human uterine endometrial cells were once established as a feeder
layer to maintain the undifferentiated state of human embryonic
stem cells, since the high expression of embryotrophic factors
and extracellular matrices plays a vital role in their growth (3).
Human endometrium thus contains a population of stem cells
responsible for this remarkable regenerative ability, and menstrual
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FIGURE 1 | Schematic representation of a decision tree based on six sources of MSCs and five different criteria related to their availability, isolation
procedure and different properties.
fluid include a population of such cells that can be expanded in
culture and still remain able to express the phenotype of multiple
lineages.
A good proliferation rate is essential for clinical applications
since cell-based therapies are dose dependent, preferably with
cells from lower passages. In most human trials, one million/kg
is the dose of choice; however, when allogenic or repeated usage
seems possible, escalating the yield of cultures becomes of utmost
importance. Nonetheless, a high proliferation is also a two-edged
sword that could lead to genetic instability or the exhaustion of
a specific stem cell pool. In fact, these MenSCs have been largely
expanded in vitro without any mutation or visible abnormality at
the chromosomal level reported so far. They maintained a telom-
erase activity greater than 50% even at passage (P) 12 compared
with human embryonic stem cells (4), and also appear to mildly
express the chemokine receptor CXCR4 and the respective receptor
for stromal cell-derived factor-1 (SDF-1), which play a significant
role in the mediation of MSC migration (5). More interestingly, in
our hands these cells did not show any sign of stem cell exhaustion
evidenced by a steady expression of stromal stem markers, a sta-
ble proliferation rate, and colony-forming-unit (CFU) potential
when comparing early (P3) versus old (P12) passages (unpub-
lished data). Such a high proliferative rate in the face of genetic
stability, with apparent preservation of multipotency, indicates this
new type of stem cell could present unexpected therapeutic prop-
erties, a fact that is also implied by their extensive differentiation
capabilities.
IMMUNOPHENOTYPE
MenSCs have been shown to be positive for mesenchymal stem
cell markers including CD9, CD29, CD105, and CD73, and
negative – as expected – for hematopoietic markers such as CD34,
CD45, and CD133 (6). However, some groups have reported
positive expression of embryonic markers such as SSEA-4 and
Nanog in MenSCs that were not found on MSCs from other
sources (7–10). This raises the question whether these cells pre-
senting earlier markers of stemness represent a more primitive
progenitor than MSCs from other sources. Nonetheless, a sec-
ond group of researchers showed a different pattern of expression
in cells isolated and cultured under comparable conditions (1).
In Table 1, we list an exhaustive comparison of published phe-
notyping profiles from all available published studies. In our
Lab, we have further characterized these cells, not only for mes-
enchymal and embryonic markers, but also for endothelial and
epithelial traits, as other cell types might represent a source of
contamination of the MenSCs culture. These quality-control para-
meters are essential when comparing similar cells from different
sources.
DIFFERENTIATION POTENTIAL AND REGENERATIVE PROPERTIES
The ability of MenSCs to differentiate into adipose, bone, cartilage,
cardiac, neural, hepatic, and pancreatic cell types has been shown
using standard differentiation techniques and media. A study by
Hida et al. using coculture with fetal mouse cardiomyocytes evi-
denced immortalization mediated by human telomerase reverse
transcriptase (hTERT) on MenSCs (13). They also demonstrated
spontaneous beating upon cardiogenic differentiation. When their
cardiac differentiation potential in a scaffold culture system differ-
entiated, MenSCs exhibited higher expression of cardiac marker
(TNNT2) when compared with induced BM-MSCs (14).
In addition, these multipotent cells had the ability to dif-
ferentiate into respiratory epithelial cells, neurocytes, myocytes,
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Table 1 | Comparison of the different immunophenotypic profile of MenSCs.














CD14 Myelomonocyte (−) (−)
CD34 Hematopoietic progenitor and stem cell,
endothelial cell
(−) (−) (−) (−) (−)
CD38 Variable levels on hematopoietic and
no-hematopoietic cell
(−) (−)
CD45 Leukocyte (−) (−) (−) (−) (−) (−)
CD133 HSC/endothelial progenitor cell (−) (−) (−) (−)
STRO-1 MSC (−)
SSEA-4 ESC (−) (+) (+)
Nanog ESC (−) (+)
CD9 MSC, hematopoietic, and epithelial cell (+) (+)
CD29 MSC (+) (+) (+) (+) (+)
CD73 B and T-lymphocyte, MSC, endothelial cell (+) (+) (+)
CD41a Megakaryocyte and platelet, found in MSC (+)
CD44 MSC, hematopoietic cell (except platelet) (+) (+) (+) (+)
CD90 Hematopoietic, MSC, T-lymphocyte (+) (+) (+) (+) (+)
CD105 MSC, vascular endothelial cell, myeloid, and
lymphoid leukocyte
(+) (+) (+) (+) (+) (+)
OCT-4 ESC (+) (+) (+) (+)
CXCR4 Stem cell chemotaxis (+) (+)
CD166 MSC, activated leukocyte (+) (+) (+)
CD49f ESC (+)
MHC I All cells (except erythrocyte) (+) (+)
MHC II APC (−) (−) (−)
LIN (−)
CD117 (c-kit) HSC/Germ cell (+) (+) (−)




CD55 MSC, hematopoietic cell (+)
CD31 Endothelial cell (−)
CD50 Leukocyte, endothelial cell (−)
CD106 Macrophage, endothelial cell (−)
Vimentin MSC (+)
Abbreviations: MSCs, mesenchymal stem cells; APC, antigen-presenting cells; ESC, embryonic stem cells; HSC, hematopoietic stem cells.
endothelial cells, pancreatic cells, hepatocytes, adipocytes, and
osteocytes (1). A recent paper, showed a comparable hepatic dif-
ferentiation ability of MenSCs with bone marrow-derived MSCs
(BM-MSCs) through the expression of many hepatic markers such
as albumin (ALB), cytokeratin 18 (CK-18), and tyrosine amino-
transferase suggesting this new source as a safe alternative to
BM-MSCs for cell-based therapies in chronic liver diseases (12).
Furthermore, the differentiation potential of MenSCs into glial lin-
eage was compared with bone marrow-stem cells (BMSCs), where
both sources showed up regulation of glial fibrillary acidic protein,
Olig-2, and MBP and down regulation of Nestin protein (15). Li
et al. showed that MenSCs present a new source for the generation

























































Khoury et al. MenSC as diagnostic/therapeutic tool
of induced pluripotent stem cells (IPS) with a high reprograming
efficiency (16).
However, it is important to note that these experiments were
conducted exclusively in vitro, and that differentiation status was
determined only phenotypically using specific antibodies (1). A
thorough investigation needs to be undertaken to validate these
claims in vivo and show that the differentiated cells possess as well
functional properties.
IMMUNOMODULATION PROPERTIES
Mesenchymal stem cells exert extensive immunomodulatory
effects in vitro and in vivo, since they have been shown to inhibit
mixed lymphocyte reaction (MLR), promote regulatory T cell
generation (Tregs) (17), and to curb T helper (Th) 1 and Th17 dif-
ferentiation among other suppressive effects. The fact they remain
hypoimmunogenic or immune privileged has allowed their suc-
cessful therapeutical use even in allo or xenogenic conditions.
However, their action seems somewhat complex, since they have
been shown to abrogate or conversely to exacerbate different (or
even the same) autoimmune disease model under varying exper-
imental conditions (18). While extensive progress has been made
to decipher the immune features of MSCs, the description of the
functional and immune effects of MenSCs is still only in its initial
stages. Bearing in mind the similarity, but also the differences dis-
played by the MSCs, we isolated from menstrual fluid – as opposed
to bone marrow – a simple extrapolation of functional or regener-
ative properties seems unwarranted. More so since the exploration
of specific functional properties and safety issues are considered a
pre-requisite to reach clinical application.
Of note, the endometrium is known to be an integral part of the
mucosal immune system. It seems uniquely poised to initiate anti-
gen specific effector as well as immunosuppressive actions, leading
to responses that are protective from infectious pathogens while
preserving the integrity of the fetus (19). It is therefore not unex-
pected that these newly discovered stem cells might exert potent
immune mediated effects. Nonetheless, there is an understand-
able dearth of clinical or even pre-clinical data at the present time,
given the recent identification of these cells. Zhong et al. reported
the feasibility of allogeneic transplantation of MenSCs into four
compassionate cases of patients with multiple sclerosis, where no
related side effects were found after a year of follow-up, though
no immune function studies were reported (20). In fact, we are
not aware of any description of the use of MenSC in autoimmune
human or animal models of disease (7). However, in a prelimi-
nary report of beneficial effects in a murine model of critical limb
ischemia, MenSCs were shown to suppress lymphocyte MLR and
the production of interferon gamma (IFN-γ) and tumor necrosis
alpha (TNF-α) in a dose dependent manner in vitro (21).
The complete assessment of the effects of MenSCs on lym-
phocyte proliferation and alloreactivity in a contact dependent
and contact independent manner in transwell experiments, in
comparison with BM-MSCs is required to fully unravel their
immunomodulatory effect. One published report indicates that
MenSCs would exert opposite effects on the MLR response at dif-
ferent target: MenSCs ratios (22). This emphasizes the need for
further studies providing insight into the mechanisms involved in
this potentially new cell therapy-based application. This includes
the evaluation of immunostimulatory molecules such as MHC I
and II, CD40, and CD80/86. While BM-MSCs have been described
to express antigen presenting (MHC I and even low level MHC
II) in response to IFN-γ, they still remain immune privileged
since they do not express co-stimulatory (CD80/86) molecules
that are required to shift the immune response from a tolerogenic
to an effector phenotype (23). Indeed, the main effect of IFN-γ
on MSCs is the final “licensing” or activation of their immuno-
suppressive and reparative properties that tend to occur mainly
in the presence of tissue damage. Thus, IFN-γ, concomitant with
TNF-α or other proinflammatory cytokines (IL-1α or IL-1β) or
mitogens (LPS), triggers a cascade of cellular events responsi-
ble for many of the immunosuppressive effects of MSCs both
in vitro and also in vivo (24–27). These entail the upregulation
of several chemokines (i.e., CCL-2/MCP-1), adhesion molecules
(VLA-4, VCAM, and the SDF-CXCR4 axis among others), and
of inducible nitric oxide synthase (iNOS) in the case of murine
MSCs. Lymphocytes then migrate into the proximity of MSCs,
where T cells are suppressed by nitric oxide (NO) (27). In the case
of human MSCs, suppression appears to be exerted by exhaustion
of tryptophane, mediated by indoleamine dehydrogenase (IDO)
instead of NO (28). In addition, non-contact dependent factors
also contribute to the immune effects of BM-MSCs, including
prostaglandin E2 (PGE2), IL-6, IL-10, Galectin-1, and TNF-α-
induced protein 6 (TSG-6) (29). These broader or even the species
specific mechanisms have not yet been analyzed in the case of
MenSCs.
Furthermore, and in an effort to understand the contrasting
clinical effect reported for MSCs in mouse models of human
rheumatoid arthritis (18, 30) and SLE (31, 32), our group has
recently evaluated the role of BM-MSCs in the differentiation of
Th1, Treg, and Th17 cells (33, 34). The balance or dysregulation
of these CD4+ helper subpopulations is a critical factor govern-
ing disease pathogenesis and clinical response in several immune
mediated diseases including murine and human SLE (35). Finding
a possible explanation for the disparate clinical results of cell ther-
apy, we initially described that MSCs suppressed Th17 cells under
resting conditions, but surprisingly, expanded them once activated
(33). In further transwell experiments, we evidenced the need for
cell contact to suppress Th17 proinflammatory cell function (34).
This methodology is currently under investigation in our group,
for the full evaluation of Th1/Th17/Treg modulating properties of
MenSCs, which are presently unknown.
THE SECRETOME AS “CELL-FREE” THERAPY
The potency in tissue restoration mediated by paracrine factors
of a broad range of bioactive molecules (secretome) produced by
MSCs has raised interest in further exploring this aspect for poten-
tial therapeutic applications. This mechanism includes various
main actions: immunomodulation, anti-apoptosis, angiogenesis
(36), and support of the growth and differentiation of local stem
and progenitor cells, and chemoattraction (37, 38). This secretion
of factors or secretome could be exploited to extend the therapeu-
tic possibilities of MSCs for treatment of a variety of diseases. The
administration of MSC-released factors or conditioned medium
(CM), could avoid some of the limiting factors associated with cell
therapy such as immune incompatibility, tumorigenicity, costs,
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and waiting time for ex vivo expansion. This would provide an
alternative option with affordable costs, excellent quality-control,
consistency, and reproducibility. A wide range of different growth
factors, cytokines, and extracellular matrix proteins (ECM) have
been identified as constituents of the in vitro cultured MSC secre-
tome. Additionally, several reports also showed that MSCs are
able to secrete large amounts of micro and nanovesicles such as
exosomes (39). The exosomes, released by most cells, are potent
mediators of cell–cell communication due their ability to transfer
proteins, lipids, and functional genetic material such as mRNA
and miRNA (40, 41). Exosomes are released from cells consti-
tutively, or following activation that significantly increases their
secretion. To date the best MSCs characterized secreted proteins
are those released by umbilical cord MSCs (UC-MSC) (42), AD
(43), and BM-MSC (44). Several authors have documented that
cells increase the liberation of vesicles in response to different
types of stresses, such as hypoxia, acidosis, oxidative stress, thermal
stress, and cytotoxic drugs (45). Since MenSCs niche, homeostasis
and physiological condition are different from the sources men-
tioned above, one can speculate that they might possess a specific
secretome signature that will differentiate them from MSCs found
in other environmental condition.
For example, the necessary activity against pathogens in the
endometrium could condition their secretome, probably through
the release of antimicrobial factors. Krasnodembskaya et al.
determined in a pneumonia mouse model that in response to
stimulation by Escherichia coli inhibiting bacterial growth (46).
At the paracrine level, little is known regarding the factors
secreted by MenSCs. Meng et al. described that MenSCs secrete
matrix metalloproteinases (MMP3 and MMP10), cytokine growth
factors [granulocyte macrophage colony-stimulating factor, GM-
CSF; platelet-derived growth factor (PDGF)-BB] and angiogenic
factors (angiopoietin-2, ANG-2) in vitro, in quantities 10–200,000
times higher than UC derived cells (1). However, no difference
was observed with others angiogenic factors like VEGF, HGF, and
EGF. While the regenerative and therapeutic potential of MenSCs-
conditioned media have not been fully evaluated in an animal
model yet, a study of an in vitro stroke model of oxygen glu-
cose deprivation (OGD) determined that OGD-exposed primary
rat neurons that were co-cultured with MenSCs or exposed to
MenSCs-conditioned medium (MenSCs-CM) exhibited a signif-
icant decrease in cell death (11). It has been recently shown that
MensCs can reverse hyperglycemia in diabetic mice most proba-
bly through paracrine factors since human insulin-producing cells
was not detected in the pancreas of the injected mice (47).
In our hands, MenSCs showed a stronger supportive poten-
tial for hematopoietic stem cell (HSC) cultures, than BM-MSCs
under cell-to-cell contact conditions (submitted data). We also
showed that the non-contact condition (transwell) resulted in the
CD34+CD133+ HSCs expansion although it was lower than that
of the direct cell interactions with the stromal cells. These results
suggest that MenSCs might display a quantitative and/or qualita-
tively distinct “secretome,” or panel of surface molecules capable
of exerting distinct contact and paracrine effects on their targets.
Furthermore, their protein expression profile can also be modi-
fied through the overexpression of factors of interest as they were
shown to be permissive for retroviral transduction (48).
Taken together, these studies suggest that MenSCs share some
properties with other MSCs but might functionally produce fac-
tors that are specific to them. This can be investigated through a
comparative analysis of their secretome under different stimula-
tion conditions, including a profiling of their exosome content.
SAFETY CONCERNS AND CLINICAL APPLICATIONS
From a safety perspective, concerns have emerged around the
procedure of collecting sterile samples, as under many countries
regulations, cell and tissue collection and storage must be done in
sterile conditions. This has been circumvented by a pre-treatment
of the collected sample with antibiotics prior to culture, and
by working in a sterile area under good manufacturing practice
(GMP) conditions with proper product release criteria. Another
concern is the development of endometriosis and the possibility
of activation or progression of dormant tumors. To address this
aspect, we performed a chronic tumorigenicity and toxicity stud-
ies, where progressive doses from 1 to 106 MenSCs were injected
subcutaneously in both male and female immunocompromised
NOD/SCID il2rγ null mice. No sign of tumor development or tox-
icity was detected after a 16 weeks follow-up (unpublished data).
In a different experimental setting (12), injected 2× 106 MenSC
in nude mice (12). According to the histological examination, no
evidence of tumor growth was found in inoculation site and the
examined tissues had no morphological characteristics of tumor
as judged by H & E staining. Moreover, to assess whether Men-
SCs modulate tumor growth, a rat glioma model was used. The
injected cells showed a substantial inhibition of the tumor growth
when compared to the control group (49).
The first report of clinical usage of MenSCs involved the allo-
genic injection of four patients with Multiple sclerosis, with a total
dose of 16–30 million cells. Treated patients showed no appar-
ent physical or serological abnormalities at follow-up (20). More
recently, Medistem, a stem cell company, launched a phase II clini-
cal trial with MenSCs, planning to enroll a total of 60 patients with
congestive heart failure, receiving escalating doses up to 200 mil-
lion cells from a universal donor. According to the published report
in 2013, 17 patients have been injected with no treatment associ-
ated adverse events reported (50). Medistem has also obtained FDA
clearance to begin Phase I trials in the US for treatment of critical
limb ischemia, an advanced form of peripheral artery disease.
In all the MenSCs studies mentioned in this review, cells were
isolated from healthy donors. There are no published reports yet
characterizing the property changes of MenSCs isolated from epi-
demiologically different background donors. Thus the effects of
age, hormonal status (post-puberty versus pre-menopausal), or
prior contraceptive usage remain unexplored. Since stem cells are
sensitive to environmental changes and stress conditions, one can
only speculate if these variations might affect their function and
properties. While it is known that proliferation and therapeutic
potential are greatly impacted by the pathological conditions of the
donors, little is known on the extent of the effect of these physio-
logical changes on MenSCs. An epidemiological study comparing
the secretome, phenotype, and immunomodulatory among other
properties would present a valuable guide for the formulation of
inclusion and exclusion criteria of donors for a stem cell-based
therapy.
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MenSCs AS A DIAGNOSTIC TOOL?
As MSCs properties are modulated by environment factors, it
also becomes important to analyze the role of these changes in
pathological conditions.
Of the 130 million newborns each year, 8 million die before
their first birthday. A contributing factor in many of these deaths
is poor pregnancy outcome as a result of a complication of preg-
nancy, including hypertensive syndromes (e.g., pre-eclampsia –
PE); poor fetal growth (e.g., intra-uterine fetal growth restric-
tion – IUGR); gestational diabetes and preterm birth. Each occurs
with an incidence of 5–10% and are responsible for the majority of
obstetric and pediatric morbidity and mortality and can perma-
nently impact on lifelong health. As an example, PE has become
one of the main causes of maternal and fetal morbidity and mor-
tality in the world, and has also been strongly associated with
an increased risk of later-life death due to cardiovascular disease,
independent from other risk factors (51–53). On the other hand,
over the past 15 years, much has been discussed and published
about the profound effects that sub-optimal health conditions
during pregnancy, especially during early stages, have on the pre-
disposition of the newborn to adult diseases (i.e., developmental
origins of disease paradigm). Therefore, the understanding of the
early processes during implantation and early stage embryo devel-
opment, will not only impact on the outcome of contemporaneous
pregnancies (including, early pregnancy loss, pre-eclampsia, intra-
uterine growth restriction, pre-term birth, gestational diabetes,
and maternal death) but also on newborn morbidity and mortal-
ity and their susceptibility. These evidence highlights the need of
accurate diagnosis of the pre-disposition to, or early detection of
disease during pregnancy, or even before that, allowing the imple-
mentation of effective treatments to prevent the occurrence of the
disease.
It is now clear that the physiopathological process of many
pregnancy diseases begins with an inadequate trophoblast invasion
early in pregnancy (54). Several hypotheses have been proposed to
explain the abnormal trophoblastic invasion early in pregnancy,
e.g., PE or IUGR, many of them suggesting that it might be trig-
gered by an altered maternal immune response or a defective
development of maternal tolerance to the allogeneic fetus. Epi-
demiological evidence supporting this idea has been published by
many groups, suggesting the importance of the maternal immune
system in the pathogenesis of placental originated diseases. Dif-
ferent studies have been performed to characterize the local and
systemic immune milieu of these patients as an explanation for
the abnormalities of placentation observed in PE (55–57). Normal
pregnancy is considered as a (T helper) Th2 type immunological
state that favors an immunosuppressive environment in order to
prevent fetal rejection (58). Since, MSCs have been widely impli-
cated in immunosuppressive mechanisms targeting a range of
target cells, in the context of antenatal screening, one area of great
interest is to identify if MenSCs are also implicated in these com-
plications. This could be achieved through a comparative study of
the changes in their immunomodulatory and paracrine factors in
comparison to MenSCs isolated from donors with uncomplicated
pregnancy history.
Recent data, suggest that microvesicles (MV) are released from
the placenta and their concentration in maternal plasma increases
during normal pregnancy (59, 60). They contain placenta-specific
proteins and miRNA and, as such, may be differentiated from
maternally derived MV (61). The concentration of exosomes has
been reported to increase in association with pre-eclampsia and
we have also established that MVs release is changed when placen-
tal cells are exposed to different environment (submitted data).
Moreover, we have been able to demonstrate that the content,
proteins, and miRNA. Therefore, complications of pregnancy that
affect placental perfusion or exposure to abnormal concentrations
of factors that modulate the release of MVs will be reflected in their
concentration and cargo in the maternal blood. It has been shown
that MSCs are among cells that produce high amount of MVs
(39), with a known therapeutical effect in myocardial ischemia
injury (62), liver fibrosis (63), and other diseases (64, 65). Since
abnormal concentration and content of placental-derived MVs in
maternal blood is a surrogate measure of placental dysfunction,
it will be of great interest to analyze the content of MVs isolated
specifically from MenSCs and study their predictive biomarker
properties in the diseases and whether they can be established as
an early diagnostic test in pre-symptomatic patients.
CONCLUSION
Although MenSCs have been tested only in very limited disease
models, these cells have been shown to possess various regenerative
properties under physiological and pathological conditions. From
a translational point of view, MenSCs appear to have practical
and also biological advantages over other stem cell sources. While
some clinical research group and companies launched clinical tri-
als using these cell, these fast developments in the face of lacking
data, underscore the need to characterize the differentiation poten-
tial and immunological properties of well defined populations of
MenSCs. The need for this type of information is decisive with
respect to the development of safe and effective cell therapies for
clinical application in human diseases.
The other to be investigated property of MenSCs is their poten-
tial as biomarkers that could be highly informative of the risk
of asymptomatic early pregnant women subsequently developing
complications of pregnancy. Such tests will offer valuable clini-
cal information that will provide an opportunity for timely and
appropriate intervention.
Future research and new evidence would greatly contribute to
propulse MenSCs to the top list of best proven source of MSCs for
new therapies and novel diagnostic tools.
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